Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas

Table 1

Reported cases of non-Hodgkin lymphoma-associated autoimmune hemolytic anemia treated with rituximab.

First author and year of publication	NHL subtype	Antibodies	Response to rituximab	Previous treatments
Lee and Kueck 1998 [20]	Marginal zone	Cold	Yes	Steroids, cyclophosphamide, plasma exchange
Bauduer 2001 [21]	Lymphoplasmacytic	Cold	Yes	Steroids, cyclophosphamide, cyclosporine, plasma exchange
Cohen et al.2001 [22]	Lymphoplasmacytic	Cold	Yes	Steroids
Layios et al. 2001 [23]	Lymphoplasmacytic	Cold	Yes	Steroids, cyclophosphamide, plasma exchange, vincristine
Mori et al. 2002 [24]	Lymphoplasmacytic	Cold	Yes	Steroids, splenectomy, chop
Paydas et al. 2003 [25]	Marginal zone	Warm	Yes	Steroids
Petit et al. 2003 [26]	Marginal zone	Cold	Yes	Steroids, chlorambucil
Fabbri et al. 2006 [27]	Marginal zone	Warm	Yes	Steroids, splenectomy, cvp
Win et al. 2007 [28]	Splenic T-cell angioimmunoblastic	Mixed	No	Steroids, intravenousImmunoglobulin, chemotherapy
Fozza et al. 2009 [29]	Marginal zone	Warm	Yes	Steroids

Abbreviations: CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone/prednisolone); CVP (cyclophosphamide, vincristine, prednisone/prednisolone); NHL (non-Hodgkin lymphoma).